Literature DB >> 11999172

Transcytosis and catabolism of antibody.

Victor Ghetie1, E Sally Ward.   

Abstract

This review describes the evolution of our knowledge of the transmission of immunoglobulin G (IgG) from mother to infant and the factors which regulate the persistence of IgG in the circulation. These apparently unrelated processes involve the same Fc receptor, FcRn (n = neonatal). FcRn appears to carry out these diverse roles by binding to IgG and then either transporting the bound IgG across cells (transcytosis) or recycling its cargo back to the cell surface (control of catabolism). IgG that is taken up by cells in the absence of binding to FcRn undergoes degradation. Thus, FcRn is the "protective" receptor that serves to maintain IgG homeostasis and deliver IgGs across cellular barriers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999172     DOI: 10.1385/IR:25:2:097

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  82 in total

1.  Identification and function of neonatal Fc receptor in mammary gland of lactating mice.

Authors:  P Cianga; C Medesan; J A Richardson; V Ghetie; E S Ward
Journal:  Eur J Immunol       Date:  1999-08       Impact factor: 5.532

2.  Cytophilic immunoglobulins revisited via natural killer cells.

Authors:  A Sulica; R B Herberman
Journal:  FASEB J       Date:  1996-11       Impact factor: 5.191

3.  The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans.

Authors:  M Firan; R Bawdon; C Radu; R J Ober; D Eaken; F Antohe; V Ghetie; E S Ward
Journal:  Int Immunol       Date:  2001-08       Impact factor: 4.823

4.  IgG-binding sites on macrophage cell membrane. I. Identification of two distinct Fc receptors on mouse peritoneal macrophages.

Authors:  A Sulica; M Gherman; C Medeşan; J Sjöquist; V Gheţie
Journal:  Eur J Immunol       Date:  1979-12       Impact factor: 5.532

5.  An Fc receptor structurally related to MHC class I antigens.

Authors:  N E Simister; K E Mostov
Journal:  Nature       Date:  1989-01-12       Impact factor: 49.962

6.  Isolation of a rabbit IgG fraction with cytophilic properties.

Authors:  M A Dobre; A Marx; V Ghetie
Journal:  J Immunol Methods       Date:  1983-05-13       Impact factor: 2.303

7.  Spontaneous in vivo isomerization of bovine serum albumin as a determinant of its normal catabolism.

Authors:  K Wallevik
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

8.  Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.

Authors:  L S Zuckier; C J Chang; M D Scharff; S L Morrison
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

9.  Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1.

Authors:  P Schuck; C G Radu; E S Ward
Journal:  Mol Immunol       Date:  1999 Oct-Nov       Impact factor: 4.407

10.  Intestinal transport of antibodies in the newborn rat.

Authors:  R Rodewald
Journal:  J Cell Biol       Date:  1973-07       Impact factor: 10.539

View more
  38 in total

1.  IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity.

Authors:  Masaru Yoshida; Atsuhiro Masuda; Timothy T Kuo; Kanna Kobayashi; Steven M Claypool; Tetsuya Takagawa; Hiromu Kutsumi; Takeshi Azuma; Wayne I Lencer; Richard S Blumberg
Journal:  Springer Semin Immunopathol       Date:  2006-10-19

Review 2.  Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse.

Authors:  Eric Peterson; S Michael Owens; Ralph L Henry
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

3.  The chicken yolk sac IgY receptor, a mammalian mannose receptor family member, transcytoses IgY across polarized epithelial cells.

Authors:  Devin B Tesar; Evelyn J Cheung; Pamela J Bjorkman
Journal:  Mol Biol Cell       Date:  2008-02-06       Impact factor: 4.138

Review 4.  Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.

Authors:  Bing-Bing Yang; Sameer Doshi; Karen Arkam; Janet Franklin; Andrew T Chow
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 5.  The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Authors:  Alina Sesarman; Gestur Vidarsson; Cassian Sitaru
Journal:  Cell Mol Life Sci       Date:  2010-03-09       Impact factor: 9.261

6.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

Review 7.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

8.  PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.

Authors:  Dhaval K Shah; Joseph P Balthasar
Journal:  Int J Pharm       Date:  2014-02-06       Impact factor: 5.875

Review 9.  Role of Fc Receptors as a therapeutic target.

Authors:  Atsuhiro Masuda; Masaru Yoshida; Hideyuki Shiomi; Yoshinori Morita; Hiromu Kutsumi; Hideto Inokuchi; Shigeto Mizuno; Akira Nakamura; Toshiyuki Takai; Richard S Blumberg; Takeshi Azuma
Journal:  Inflamm Allergy Drug Targets       Date:  2009-03

10.  FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.

Authors:  Hyuncheol Kim; Shaun B Robinson; Karl G Csaky
Journal:  Mol Vis       Date:  2009-12-16       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.